Rapid Rise in PSA Levels a Poor Predictor of Prostate
THURSDAY, Feb. 24 (HealthDay News) -- Blood tests that indicate
prostate-specific antigen (PSA) levels are rising rapidly over time
are of little use in detecting aggressive prostate cancer and
should not be done, a new study indicates.
PSA is a protein produced by cells of the prostate gland. High
levels of PSA can be a marker for prostate cancer, although it's
far from a perfect screening tool, experts say. Men with both high
and low levels of PSA can have cancer or not have cancer.
The thought was that since high PSA levels are correlated with
prostate cancer, rapidly rising levels of PSA, called "PSA
velocity," from one year to another would also be an indicator of
However, the new study found that PSA velocity doesn't add any
useful information beyond what physicians can already tell from
other methods of prostate cancer screening, including the one-time
PSA level test and digital rectal exams.
Current screening guidelines that recommend biopsies for men who
have high PSA velocity but no other signs of prostate cancer --
such as a suspected abnormality during a digital rectal exam or
high PSA level during a single test -- are leading to many
unnecessary biopsies, the researchers said.
"We found there was no strong association between PSA velocity and prostate cancer, and virtually none with aggressive prostate cancer," said study author Andrew Vickers, of Memorial Sloan-Kettering Cancer Center in New York City. "The velocity didn't add anything more to detecting aggressive prostate cancers."
The study is published online Feb. 24 in the
Journal of the National Cancer Institute.
The whole issue of prostate cancer screening -- including the
PSA test, the digital rectal exam and PSA velocity -- has been
controversial, said Dr. Otis Brawley, chief medical officer of the
American Cancer Society (ACS).
Part of the difficulty is, while current screening methods are
good at detecting cancer, they can't distinguish between
aggressive, life-threatening prostate cancers and those that are
slow-growing and relatively benign. And many prostate cancers are
just that -- of little risk to men during their lifetimes, Brawley
Current ACS prostate screening cancer guidelines recommend that
men make an informed decision with their doctor about whether to be
tested for prostate cancer. "Research has not yet proven that the
potential benefits of testing outweigh the harms of testing and
treatment," according to the ACS.
As for PSA velocity, the ACS doesn't have a position on what PSA
velocity warrants a biopsy.
But the National Comprehensive Cancer Network and American
Urological Association guidelines do recommend biopsies based on
high PSA velocities, even in the absence of an elevated PSA or a
suspicious digital rectal exam, according to background information
in the study.
And many internal medicine and primary-care doctors, in part
because of fears of litigation, do order biopsies based on
fast-rising PSA levels, Brawley said.
"It's something that has become almost a community standard. If a guy has a PSA of .8 last year, and a year or so later you've repeated it and it's 1.9, because it has increased by a factor of 1 he gets sent to biopsy," Brawley said.
In the study, researchers used data on more than 5,500 men in
their 60s and 70s who took part in a drug trial for a prostate
cancer prevention drug. The men in the study were all from the
placebo arm, meaning they had not received the drug. As part of the
trial, all of the men agreed to have a biopsy at the end of the
trial, needed or not.
Researchers did find a statistical association between PSA
velocity and the chances of a biopsy coming back cancerous. But
when they factored in other things that can influence risk,
including a family history of the disease, being older, being
black, PSA level and results of a digital rectal exam, there was
virtually no association between PSA velocity and biopsy
"PSA velocity measurement is not useful," Brawley said.
Grace Lu-Yao, a cancer epidemiologist at the Cancer Institute of
New Jersey who wrote an accompanying editorial, said she agreed
with the authors' conclusions that PSA velocity does not seem to be
a good predictor of prostate cancer.
In addition, tracking PSA levels overtime can also cause anxiety
to men, who often worry if their PSA level has suddenly shot
"According to the data, PSA velocity does not add any value, but it may add more anxiety," Lu-Yao said.
National Cancer Institute has more on the PSA
Copyright © 2011
. All rights reserved.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.